Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, Egypt
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 295
- 试验地点
- 2
- 主要终点
- Number of participants with Liver disease
研究概览
简要总结
Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today
详细描述
All-cause mortality rates have declined substantially in several high-income countries, including England.
A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex.
Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially.
Many studies have primarily focused on identifying multimorbidity patterns in the general population.
The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with type 2 diabetes.
排除标准
- •Patients with type 1 diabetes.
- •Patients with secondary diabetes.
研究组 & 干预措施
type 2 DM
干预措施: HBA1C (Diagnostic Test)
type 2 DM
干预措施: Thyroid-stimulating hormone (Diagnostic Test)
type 2 DM
干预措施: Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides (Diagnostic Test)
type 2 DM
干预措施: Urine analysis and urinary albumin-to-creatinine ratio (Diagnostic Test)
type 2 DM
干预措施: Serum creatinine and estimated glomerular filtration rate (Diagnostic Test)
type 2 DM
干预措施: Complete blood count (Diagnostic Test)
type 2 DM
干预措施: Serum iron, TIBC, Transferrin saturation and serum ferritin if needed (Diagnostic Test)
type 2 DM
干预措施: Electrocardiography (ECG) (Procedure)
type 2 DM
干预措施: Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound (Procedure)
type 2 DM
干预措施: Arterial duplex ultrasound of both lower limbs (Procedure)
type 2 DM
干预措施: Random blood glucose (Diagnostic Test)
type 2 DM
干预措施: AST, ALT, albumin (Diagnostic Test)
结局指标
主要结局
Number of participants with Liver disease
时间窗: At time of inclusion in the study
Number of participants with hypertension
时间窗: At time of inclusion in the study
Number of participants with thyroid disorder
时间窗: At time of inclusion in the study
Number of participants with Coronary heart disease
时间窗: At time of inclusion in the study
Number of participants with Infections
时间窗: At time of inclusion in the study
Number of participants with dyslipidemia
时间窗: At time of inclusion in the study
Number of participants with Diabetic kidney disease
时间窗: At time of inclusion in the study
Number of participants with Stroke
时间窗: At time of inclusion in the study
Number of participants with Peripheral arterial disease
时间窗: At time of inclusion in the study
Number of participants with Diabetic eye disease
时间窗: At time of inclusion in the study
Number of participants with Peripheral neuropathy
时间窗: At time of inclusion in the study
Number of participants with Cancer
时间窗: At time of inclusion in the study
次要结局
- Number of participants with controlled diabetes mellitus with correlation to the number of cormobidity(At time of inclusion in the study)
- Correlate the presence of each co-morbidity with the extent of diabetes control(At time of inclusion in the study)
研究者
Asmaa Nady Hussein
Lecturer of Internal Medicine and Clinical Hematology
New Valley University
